10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Microglial inclusions and neurofilament light chain release follow neuronal α-synuclein lesions in long-term brain slice cultures

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Proteopathic brain lesions are a hallmark of many age-related neurodegenerative diseases including synucleinopathies and develop at least a decade before the onset of clinical symptoms. Thus, understanding of the initiation and propagation of such lesions is key for developing therapeutics to delay or halt disease progression.

          Methods

          Alpha-synuclein (αS) inclusions were induced in long-term murine and human slice cultures by seeded aggregation. An αS seed-recognizing human antibody was tested for blocking seeding and/or spreading of the αS lesions. Release of neurofilament light chain (NfL) into the culture medium was assessed.

          Results

          To study initial stages of α-synucleinopathies, we induced αS inclusions in murine hippocampal slice cultures by seeded aggregation. Induction of αS inclusions in neurons was apparent as early as 1week post-seeding, followed by the occurrence of microglial inclusions in vicinity of the neuronal lesions at 2–3 weeks. The amount of αS inclusions was dependent on the type of αS seed and on the culture’s genetic background (wildtype vs A53T-αS genotype). Formation of αS inclusions could be monitored by neurofilament light chain protein release into the culture medium, a fluid biomarker of neurodegeneration commonly used in clinical settings. Local microinjection of αS seeds resulted in spreading of αS inclusions to neuronally connected hippocampal subregions, and seeding and spreading could be inhibited by an αS seed-recognizing human antibody. We then applied parameters of the murine cultures to surgical resection-derived adult human long-term neocortical slice cultures from 22 to 61-year-old donors. Similarly, in these human slice cultures, proof-of-principle induction of αS lesions was achieved at 1week post-seeding in combination with viral A53T-αS expressions.

          Conclusion

          The successful translation of these brain cultures from mouse to human with the first reported induction of human αS lesions in a true adult human brain environment underlines the potential of this model to study proteopathic lesions in intact mouse and now even aged human brain environments.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s13024-021-00471-2.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          alpha-Synuclein is phosphorylated in synucleinopathy lesions.

          The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Importantly, the identification of missense mutations in the alpha-synuclein gene in some pedigrees of familial PD has strongly implicated alpha-synuclein in the pathogenesis of PD and other synucleinopathies. However, specific post-translational modifications that underlie the aggregation of alpha-synuclein in affected brains have not, as yet, been identified. Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions. Furthermore, phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro. These results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.

            Parkinson's disease is characterized by abundant α-synuclein (α-Syn) neuronal inclusions, known as Lewy bodies and Lewy neurites, and the massive loss of midbrain dopamine neurons. However, a cause-and-effect relationship between Lewy inclusion formation and neurodegeneration remains unclear. Here, we found that in wild-type nontransgenic mice, a single intrastriatal inoculation of synthetic α-Syn fibrils led to the cell-to-cell transmission of pathologic α-Syn and Parkinson's-like Lewy pathology in anatomically interconnected regions. Lewy pathology accumulation resulted in progressive loss of dopamine neurons in the substantia nigra pars compacta, but not in the adjacent ventral tegmental area, and was accompanied by reduced dopamine levels culminating in motor deficits. This recapitulation of a neurodegenerative cascade thus establishes a mechanistic link between transmission of pathologic α-Syn and the cardinal features of Parkinson's disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease

              Analysis of human pathology led Braak to postulate that α-synuclein (α-syn) pathology could spread from the gut to brain via the vagus nerve. Here, we test this postulate by assessing α-synucleinopathy in the brain in a novel gut-to-brain α-syn transmission mouse model, where pathological α-syn preformed fibrils were injected into the duodenal and pyloric muscularis layer. Spread of pathologic α-syn in brain, as assessed by phosphorylation of serine 129 of α-syn, was observed first in the dorsal motor nucleus, then in caudal portions of the hindbrain, including the locus coeruleus, and much later in basolateral amygdala, dorsal raphe nucleus, and the substantia nigra pars compacta. Moreover, loss of dopaminergic neurons and motor and non-motor symptoms were observed in a similar temporal manner. Truncal vagotomy and α-syn deficiency prevented the gut-to-brain spread of α-synucleinopathy and associated neurodegeneration and behavioral deficits. This study supports the Braak hypothesis in the etiology of idiopathic Parkinson's disease (PD).
                Bookmark

                Author and article information

                Contributors
                barthmelanie@gmx.net
                mb2262@cam.ac.uk
                niklas.schwarz@uni-tuebingen.de
                renata.werner@posteo.de
                jb2274@cam.ac.uk
                marc.welzer@uni-tuebingen.de
                smazzitelli1@gmail.com
                Lisa.Haesler@dzne.de
                manuels@mrc-lmb.cam.ac.uk
                Thomas.Wuttke@med.uni-tuebingen.de
                deborah.kronenberg-versteeg@uni-tuebingen.de
                KAPE@Lundbeck.com
                MAAM@lundbeck.com
                ania.alik@cnrs.fr
                ronald.melki@cnrs.fr
                philipp.kahle@uni-tuebingen.de
                derya.shimshek@novartis.com
                hkoch@ukaachen.de
                mathias.jucker@uni-tuebingen.de
                gaye.tanrioever@uni-tuebingen.de
                Journal
                Mol Neurodegener
                Mol Neurodegener
                Molecular Neurodegeneration
                BioMed Central (London )
                1750-1326
                11 August 2021
                11 August 2021
                2021
                : 16
                : 54
                Affiliations
                [1 ]GRID grid.424247.3, ISNI 0000 0004 0438 0426, DZNE, German Center for Neurodegenerative Diseases, ; 72076 Tuebingen, Germany
                [2 ]GRID grid.428620.a, Department of Cellular Neurology, , Hertie Institute for Clinical Brain Research, University of Tuebingen, ; 72076 Tuebingen, Germany
                [3 ]GRID grid.10392.39, ISNI 0000 0001 2190 1447, Graduate Training Center of Neuroscience, University of Tuebingen, ; 72076 Tuebingen, Germany
                [4 ]GRID grid.428620.a, Department of Neurology and Epileptology, , Hertie Institute for Clinical Brain Research, University of Tuebingen, ; 72076 Tuebingen, Germany
                [5 ]GRID grid.10392.39, ISNI 0000 0001 2190 1447, Department of Neurosurgery, , University of Tuebingen, ; 72076 Tuebingen, Germany
                [6 ]GRID grid.424580.f, ISNI 0000 0004 0476 7612, Division of Neuroscience, H. Lundbeck A/S, ; 2500 Valby, Denmark
                [7 ]GRID grid.457286.a, ISNI 0000 0004 0416 9567, MIRCen, CEA and Laboratory of Neurodegenerative Diseases, CNRS, , Institut François Jacob, ; 92265 Fontenay-aux-Roses, France
                [8 ]GRID grid.428620.a, Laboratory of Functional Neurogenetics, Department of Neurodegeneration, , Hertie-Institute for Clinical Brain Research, University of Tuebingen, ; 72076 Tuebingen, Germany
                [9 ]GRID grid.419481.1, ISNI 0000 0001 1515 9979, Neuroscience Research, , Novartis Institutes for BioMedical Research, ; CH-4056 Basel, Switzerland
                [10 ]GRID grid.1957.a, ISNI 0000 0001 0728 696X, Department of Epileptology, Neurology, RWTH Aachen University, ; Aachen, Germany
                Author information
                http://orcid.org/0000-0002-5252-8443
                Article
                471
                10.1186/s13024-021-00471-2
                8356412
                34380535
                a31b1f0d-4604-4ab7-b001-99f8265a2626
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 9 April 2021
                : 6 July 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100010767, Innovative Medicines Initiative;
                Award ID: 116060
                Award Recipient :
                Funded by: Hertie Institute for Clinical Brain Research (8868)
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2021

                Neurosciences
                alpha-synuclein,microglia,neurofilament light chain,slice culture
                Neurosciences
                alpha-synuclein, microglia, neurofilament light chain, slice culture

                Comments

                Comment on this article